Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.

Authors :: Bourlon, Maria Teresa
Escudier, Bernard
Burotto, Mauricio
Powles, Thomas
Apolo, Andrea B.
Shah, Amishi Yogesh
Porta, Camillo
Suárez, Cristina
Barrios, Carlos H.
Richardet, Martin
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
Wang, Fong
Wang, Peter
Panzica, Julie
Fedorov, Viktor
Motzer, Robert J.
Choueiri, Toni K.
Source :: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p362-362, 140p
Publication Year :: 2024

Full Text Access

Tools